Claims
- 1. A method comprising:
a) administering to at least a portion of the blood of a subject predisposed to an autoimmune disease, a photoactivatable compound before the clinical manifestation of a symptom associated with said autoimmune disease; and b) treating said portion of the blood of said subject with light of a wavelength that activates said photoactivatable compound, before the clinical manifestation of a symptom associated with said autoimmune disease.
- 2. The method of claim 1, wherein steps a)-b) are carried out after the identification of a disease marker for said autoimmune disease in said subject.
- 3. The method of claim 2, wherein said disease marker is selected from the group consisting of genetic marker, serological marker, immunological marker, gene expression profile, protein expression profile, and polymorphism.
- 4. The method of claim 1, wherein said predisposition is determined by the identification of a disease marker for said autoimmune disease in said subject.
- 5. The method of claim 4, wherein said disease marker is selected from the group consisting of genetic marker, serological marker, immunological marker, gene expression profile, protein expression profile, and polymorphism.
- 6. The method of claim 1, further comprising repeating steps a)-b) according to a schedule selected from the group consisting of weekly, monthly, twice a month, three times a month, every other month, every three months, every six months, every nine months, and yearly.
- 7. The method of claim 1, wherein said photoactivatable compound comprises a psoralen or psoralen derivative.
- 8. The method of claim 7, wherein said psoralen or psoralen derivative comprises 8-methoxypsoralen.
- 9. The method of claim 7, wherein said psoralen or psoralen derivative comprises amotosalen.
- 10. The method of claim 1, wherein said autoimmune disease is selected from the group consisting of alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, Graves' disease, Guillain-Barré, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), IgA nephropathy, insulin dependent diabetes, juvenile arthritis, lichen planus, ménière's disease, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, stiff-man syndrome, systematic lupus erythematosus, Takayasu arteritis, temporal arteritis/giant cell arteritis, ulcerative colitis, uveitis, vasculitis, vitiligo, and Wegener's granulomatosis.
- 11. A method comprising:
a) administering to at least a portion of the blood of a subject predisposed to an atopic disease, a photoactivatable compound before the clinical manifestation of a symptom associated with said atopic disease; and b) treating said portion of the blood of said subject with light of a wavelength that activates said photoactivatable compound, before the clinical manifestation of a symptom associated with said atopic disease.
- 12. The method of claim 11, wherein steps a)-b) are carried out after the identification of a disease marker for said atopic disease in said subject.
- 13. The method of claim 12, wherein said disease marker is selected from the group consisting of genetic marker, serological marker, immunological marker, gene expression profile, protein expression profile, and polymorphism.
- 14. The method of claim 11, wherein said predisposition is determined by the identification of a disease marker for said atopic disease in said subject.
- 15. The method of claim 14, wherein said disease marker is selected from the group consisting of genetic marker, serological marker, immunological marker, gene expression profile, protein expression profile, and polymorphism.
- 16. The method of claim 11, further comprising repeating steps a)-b) according to a schedule selected from the group consisting of weekly, monthly, twice a month, three times a month, every other month, every three months, every six months, every nine months, and yearly.
- 17. The method of claim 11, wherein said photoactivatable compound comprises a psoralen or psoralen derivative.
- 18. The method of claim 17, wherein said psoralen or psoralen derivative comprises 8-methoxypsoralen.
- 19. The method of claim 17, wherein said psoralen or psoralen derivative comprises amotosalen.
- 20. The method of claim 11, wherein said atopic disease is selected from the group consisting of atopic dermatitis, extrinsic bronchial asthma, urticaria, allergic rhinitis, and allergic enterogastritis.
- 21. A method comprising:
a) administering to at least a portion of the blood of a subject predisposed to an autoimmune reaction manifested by a T-cell response, a photoactivatable compound before the clinical manifestation of a symptom associated with said autoimmune reaction; and b) treating said portion of the blood of said subject with light of a wavelength that activates said photoactivatable compound, before the clinical manifestation of a symptom associated with said autoimmune reaction.
- 22. The method of claim 21, wherein steps a)-b) are carried out after the identification of a disease marker for said autoimmune reaction in said subject.
- 23. The method of claim 22, wherein said disease marker is selected from the group consisting of genetic marker, serological marker, immunological marker, gene expression profile, protein expression profile, and polymorphism.
- 24. The method of claim 21, wherein said predisposition is determined by the identification of a disease marker for said autoimmune reaction in said subject.
- 25. The method of claim 24, wherein said disease marker is selected from the group consisting of genetic marker, serological marker, immunological marker, gene expression profile, protein expression profile, and polymorphism.
- 26. The method of claim 21, further comprising repeating steps a)-b) according to a schedule selected from the group consisting of weekly, monthly, twice a month, three times a month, every other month, every three months, every six months, every nine months, and yearly.
- 27. The method of claim 21, wherein said photoactivatable compound comprises a psoralen or psoralen derivative.
- 28. The method of claim 27, wherein said psoralen or psoralen derivative comprises 8-methoxypsoralen.
- 29. The method of claim 27, wherein said psoralen or psoralen derivative comprises amotosalen.
- 30. The method of claim 21, wherein said autoimmune reaction is associated with a transplant selected from the group consisting of organ transplant, tissue transplant, bone marrow transplant, and stem cell transplant.
- 31. The method of claim 21, wherein said autoimmune reaction is associated with a disease selected from the group consisting of autoimmune disease and atopic disease.
- 32. A method comprising:
a) administering to at least a portion of the blood of a transplant donor, a photoactivatable compound prior to harvesting said transplant from said donor; and b) treating said portion of the blood of said transplant donor with light of a wavelength that activates said photoactivatable compound, prior to harvesting said transplant from said donor.
- 33. The method of claim 32, wherein steps a)-b) are carried out according to a schedule selected from the group consisting of two days, one week prior to harvesting said transplant; three days, one week prior to harvesting said transplant; two days a week for two weeks prior to harvesting said transplant; and three days a week for three weeks prior to harvesting said transplant.
- 34. The method of claim 32, wherein said photoactivatable compound comprises a psoralen or psoralen derivative.
- 35. The method of claim 34, wherein said psoralen or psoralen derivative comprises 8-methoxypsoralen.
- 36. The method of claim 34, wherein said psoralen or psoralen derivative comprises amotosalen.
- 37. The method of claim 32, further comprising the steps of:
c) administering to at least a portion of the blood of a recipient of said transplant, a photoactivatable compound prior to said recipient receiving said transplant; and d) treating said portion of the blood of said recipient with light of a wavelength that activates said photoactivatable compound, prior to said recipient receiving said transplant.
- 38. The method of claim 37, wherein steps a)-b) are carried out according to a schedule selected from the group consisting of two days, one week prior to said recipient receiving said transplant; three days, one week prior to said recipient receiving said transplant; two days a week for two weeks prior to said recipient receiving said transplant; and three days a week for three weeks prior to said recipient receiving said transplant.
- 39. The method of claim 37, wherein said photoactivatable compound comprises a psoralen or psoralen derivative.
- 40. The method of claim 39, wherein said psoralen or psoralen derivative comprises 8-methoxypsoralen.
- 41. The method of claim 39, wherein said psoralen or psoralen derivative comprises amotosalen.
- 42. The method of claim 37, further comprising:
e) administering to at least a portion of the blood of said recipient of said transplant, a photoactivatable compound after said recipient receives said transplant; and f) treating said portion of the blood of said receipient with light of a wavelength that activates said photoactivatable compound, after said recipient receives said transplant.
- 43. The method of claim 42, further comprising repeating steps e)-f) according to a schedule selected from the group consisting of weekly, monthly, twice a month, three times a month, every other month, every three months, every six months, every nine months, and yearly.
- 44. The method of claim 42, wherein said photoactivatable compound comprises a psoralen or psoralen derivative.
- 45. The method of claim 44, wherein said psoralen or psoralen derivative comprises 8-methoxypsoralen.
- 46. The method of claim 44, wherein said psoralen or psoralen derivative comprises amotosalen.
- 47. The method of claim 32, wherein said transplant is selected from the group consisting of organ, tissue, stem cell, and bone marrow.
- 48. The method of claim 47, wherein said organ transplant is an organ graft selected from the group consisting of syngeneic graft, allograft, and xenograft.
- 49. The method of claim 47, wherein said organ is selected from the group consisting heart, liver, pancreas, pancreatic islets, kidney, lung, larynx, stem cells, eyes, cornea, muscle, and skin.
- 50. The method of claim 47, wherein said organ is selected from the group consisting of human, artificial, clonal, and mammalian.
- 51. The method of claim 50, wherein said artificial organ is selected from the group consisting of heart, liver, pancreas, kidney, lung, pancreatic islets, larynx, blood, stem cells, eyes, cornea, muscle, and skin.
- 52. The method of claim 47, wherein said tissue transplant is a tissue graft selected from the group consisting of autograft, syngeneic graft, allograft, and xenograft.
- 53. The method of claim 47, wherein said tissue is selected from the group consisting of cartilage, bone, liver, small-bowel, neuronal, adrenal medullary tissue, fetal thymus tissue, and parathyroid tissue.
- 54. The method of claim 47, wherein said tissue is selected from the group consisting of human, artificial, clonal, and mammalian.
- 55. The method of claim 54, wherein said artificial tissue is selected from the group consisting of cartilage, bone, liver, small-bowel, neuronal, adrenal medullary tissue, fetal thymus tissue, and parathyroid tissue.
- 56. The method of claim 47, wherein said stem cell transplant is selected from the group consisting of allogeneic and xenogeneic.
- 57. The method of claim 47, wherein said stem cell is selected from the group consisting of ectoderm, endoderm, mesenchymal, or any cells derived therefrom.
- 58. The method of claim 47, wherein said bone marrow transplant is selected from the group consisting of allogeneic and xenogeneic.
- 59. A method comprising:
a) administering to at least a portion of the blood of a recipient of a transplant, a photoactivatable compound prior to said recipient receiving said transplant; and b) treating said portion of the blood of said recipient with light of a wavelength that activates said photoactivatable compound, prior to said recipient receiving said transplant.
- 60. The method of claim 59, wherein steps a)-b) are carried out according to a schedule selected from the group consisting of two days, one week prior to said recipient receiving said transplant; three days, one week prior to said recipient receiving said transplant; two days a week for two weeks prior to said recipient receiving said transplant; and three days a week for three weeks prior to said recipient receiving said transplant.
- 61. The method of claim 59, wherein said photoactivatable compound comprises a psoralen or psoralen derivative.
- 62. The method of claim 61, wherein said psoralen or psoralen derivative comprises 8-methoxypsoralen.
- 63. The method of claim 61, wherein said psoralen or psoralen derivative comprises amotosalen.
- 64. The method of claim 59 further comprising:
c) administering to at least a portion of the blood of said recipient of said transplant, a photoactivatable compound after said recipient receives said transplant; and d) treating said portion of the blood of said recipient with light of a wavelength that activates said photoactivatable compound, after said recipient receives said transplant.
- 65. The method of claim 64, further comprising repeating steps c)-d) according to a schedule selected from the group consisting of weekly, monthly, twice a month, three times a month, every other month, every three months, every six months, every nine months, and yearly.
- 66. The method of claim 64, wherein said photoactivatable compound comprises a psoralen or psoralen derivative.
- 67. The method of claim 66, wherein said psoralen or psoralen derivative comprises 8-methoxypsoralen.
- 68. The method of claim 66, wherein said psoralen or psoralen derivative comprises amotosalen.
- 69. The method of claim 59, wherein said transplant is selected from the group consisting of organ, tissue, and stem cell.
- 70. The method of claim 69, wherein said organ transplant is an organ graft selected from the group consisting of syngeneic graft, allograft, and xenograft.
- 71. The method of claim 69, wherein said organ is selected from the group consisting heart, liver, pancreas, pancreatic islets, kidney, lung, larynx, stem cells, eyes, cornea, muscle, and skin.
- 72. The method of claim 69, wherein said organ is selected from the group consisting of human, artificial, clonal, and mammalian.
- 73. The method of claim 72, wherein said artificial organ is selected from the group consisting of heart, liver, pancreas, kidney, lung, pancreatic islets, larynx, blood, stem cells, eyes, cornea, muscle, and skin.
- 74. The method of claim 69, wherein said tissue transplant is a tissue graft selected from the group consisting of autograft, syngeneic graft, allograft, and xenograft.
- 75. The method of claim 69, wherein said tissue is selected from the group consisting of cartilage, bone, liver, small-bowel, neuronal, adrenal medullary tissue, fetal thymus tissue, and parathyroid tissue.
- 76. The method of claim 69, wherein said tissue is selected from the group consisting of human, artificial, clonal, and mammalian.
- 77. The method of claim 76, wherein said artificial tissue is selected from the group consisting of cartilage, bone, liver, small-bowel, neuronal, adrenal medullary tissue, fetal thymus tissue, and parathyroid tissue.
- 78. The method of claim 69, wherein said stem cell transplant is selected from the group consisting of allogeneic and xenogeneic.
- 79. The method of claim 69, wherein said stem cell is selected from the group consisting of ectoderm, endoderm, mesenchymal, or any cells derived therefrom.
- 80. A method comprising:
a) administering to at least a portion of the blood of a transplant donor, a photoactivatable compound prior to harvesting said transplant from said donor; and b) treating said portion of the blood of said transplant donor with light of a wavelength that activates said photoactivatable compound, prior to harvesting said transplant from said donor.
- 81. The method of claim 80, wherein steps a)-b) are carried out according to a schedule selected from the group consisting of two days, one week prior to harvesting said transplant; three days, one week prior to harvesting said transplant; two days a week for two weeks prior to harvesting said transplant; and three days a week for three weeks prior to harvesting said transplant.
- 82. The method of claim 80, wherein said photoactivatable compound comprises a psoralen or psoralen derivative.
- 83. The method of claim 82, wherein said psoralen or psoralen derivative comprises 8-methoxypsoralen.
- 84. The method of claim 82, wherein said psoralen or psoralen derivative comprises amotosalen.
- 85. The method of claim 80 further comprising:
c) administering to at least a portion of the blood of a recipient of said transplant, a photoactivatable compound after said recipient receives said transplant; and d) treating said portion of the blood of said recipient with light of a wavelength that activates said photoactivatable compound, after said recipient receives said transplant.
- 86. The method of claim 85, further comprising repeating steps c)-d) according to a schedule selected from the group consisting of weekly, monthly, twice a month, three times a month, every other month, every three months, every six months, every nine months, and yearly.
- 87. The method of claim 85, wherein said photoactivatable compound comprises a psoralen or psoralen derivative.
- 88. The method of claim 87, wherein said psoralen or psoralen derivative comprises 8-methoxypsoralen.
- 89. The method of claim 87, wherein said psoralen or psoralen derivative comprises amotosalen.
- 90. The method of claim 80, wherein said transplant is selected from the group consisting of organ, tissue, stem cell, and bone marrow.
- 91. The method of claim 90, wherein said organ transplant is an organ graft selected from the group consisting of syngeneic graft, allograft, and xenograft.
- 92. The method of claim 90, wherein said organ is selected from the group consisting heart, liver, pancreas, pancreatic islets, kidney, lung, larynx, stem cells, eyes, cornea, muscle, and skin.
- 93. The method of claim 90, wherein said organ is selected from the group consisting of human, artificial, clonal, and mammalian.
- 94. The method of claim 93, wherein said artificial organ is selected from the group consisting of heart, liver, pancreas, kidney, lung, pancreatic islets, larynx, blood, stem cells, eyes, cornea, muscle, and skin.
- 95. The method of claim 90, wherein said tissue transplant is a tissue graft selected from the group consisting of autograft, syngeneic graft, allograft, and xenograft.
- 96. The method of claim 90, wherein said tissue is selected from the group consisting of cartilage, bone, liver, small-bowel, neuronal, adrenal medullary tissue, fetal thymus tissue, and parathyroid tissue.
- 97. The method of claim 90, wherein said tissue is selected from the group consisting of human, artificial, clonal, and mammalian.
- 98. The method of claim 97, wherein said artificial tissue is selected from the group consisting of cartilage, bone, liver, small-bowel, neuronal, adrenal medullary tissue, fetal thymus tissue, and parathyroid tissue.
- 99. The method of claim 90, wherein said stem cell transplant is selected from the group consisting of allogeneic and xenogeneic.
- 100. The method of claim 90, wherein said stem cell is selected from the group consisting of ectoderm, endoderm, mesenchymal, or any cells derived therefrom.
- 101. The method of claim 90, wherein said bone marrow transplant is selected from the group consisting of allogeneic and xenogeneic.
- 102. A method comprising:
a) administering to at least a portion of the blood of a recipient of an implant, a photoactivatable compound prior to said recipient receiving said implant; and b) treating said portion of the blood of said subject with light of a wavelength that activates said photoactivatable compound, prior to said recipient receiving said implant.
- 103. The method of claim 102, wherein steps a)-b) are carried out according to a schedule selected from the group consisting of two days, one week prior to said recipient receiving said implant; three days, one week prior to said recipient receiving said implant; two days a week for two weeks prior to said recipient receiving said implant; and three days a week for three weeks prior to said recipient receiving said implant.
- 104. The method of claim 102, wherein said photoactivatable compound comprises a psoralen or psoralen derivative.
- 105. The method of claim 104 wherein said psoralen or psoralen derivative comprises 8-methoxypsoralen.
- 106. The method of claim 104, wherein said psoralen or psoralen derivative comprises amotosalen.
- 107. The method of claim 102 further comprising:
c) administering to at least a portion of the blood of said recipient of said implant, a photoactivatable compound after said recipient receives said implant; and d) treating said portion of the blood of said implant recipient with light of a wavelength that activates said photoactivatable compound, after said recipient receives said implant.
- 108. The method of claim 107, further comprising repeating steps c)-d) according to a schedule selected from the group consisting of weekly, monthly, twice a month, three times a month, every other month, every three months, every six months, every nine months, and yearly.
- 109. The method of claim 107, wherein said photoactivatable compound comprises a psoralen or psoralen derivative.
- 110. The method of claim 109 wherein said psoralen or psoralen derivative comprises 8-methoxypsoralen.
- 111. The method of claim 109, wherein said psoralen or psoralen derivative comprises amotosalen.
- 112. The method of claim 102, wherein said implant is selected from the group consisting of spinal, vertebral, bone repair, bone replacement, joint replacement, metal plate, facial, hair, collagen, prostate seed, breast, hormonal, pacemaker, defibrillator, cochlear, muscle, and cortical.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present application is related to and claims, under 35 U.S.C. § 119(e), the benefit of U.S. Provisional Patent Application Serial No. 60/333,746, filed 29 November 2001, which is entirely expressly incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60333746 |
Nov 2001 |
US |